TherapeuticsMD (TXMD) Reports In-Line Q4 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Noble Trims PT on TherapeuticsMD (TXMD) to $17.50 Following Q4 Results; Affirms at 'Buy'
February 26, 2016 12:09 PM ESTNoble Financial affirms TherapeuticsMD (NYSE: TXMD) with a Buy rating, but trimmed its price target from $18 down to $17.50 following the company's Q4 report issued... More
